Related Experiment Video
Updated: Jan 21, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
Published on: June 26, 2014
Potential Drug Targets Against Hepatitis B Virus Based on Both Virus and Host Factors
Bing-Yi Zhang1, Dan-Ping Chai1, Yi-Hang Wu1
1Department of Pharmacy, Zhejiang Provincial Key Laboratory of Biometrology and Inspection & Quarantine, College of Life Sciences, China Jiliang University, Hangzhou 310018, China.
Insights
Discovering new hepatitis B virus (HBV) drug targets is crucial due to existing treatment limitations and drug resistance. This review summarizes viral, host, and immune targets for developing innovative HBV therapies.
Area of Science:
- Hepatology
- Virology
- Drug Discovery
Background:
- Hepatitis B virus (HBV) infection remains a significant global health burden despite available vaccines.
- Current treatments like nucleoside analogues and interferon-alpha have limitations, including drug resistance due to HBV genome variability.
- There is an urgent need for novel therapeutic strategies and drugs to effectively cure chronic hepatitis B.
Purpose of the Study:
- To provide theoretical support for the development of innovative anti-HBV drugs.
- To summarize current antiviral targets against hepatitis B virus infection.
- To guide the design of new therapeutic agents by reviewing potential targets.
Main Methods:
- Analysis of advances in potential drug targets for anti-HBV infection.
- Focus on targeting the virus genome, host cellular functions, and virus-host protein interactions.
- Emphasis on immune targets against chronic hepatitis B.
Main Results:
- HBV, an obligate intracellular parasite, relies on host cell machinery for replication.
- Targeting both viral and host factors presents a promising therapeutic approach.
- A comprehensive summary of antiviral strategies targeting viral, host, and immune factors is presented.
Conclusions:
- The review offers a summary of antiviral therapeutic strategies for HBV infection.
- It highlights the importance of targeting virus, host, and immune factors for future drug design.
- This work supports the development of innovative drugs against HBV.
Background:
Hepatitis B is a very harmful and epidemic disease caused by hepatitis B virus (HBV). Although an effective anti-HBV vaccine is available, chronic infection poses still a huge health burden in the whole world. The present anti-HBV drugs including nucleoside analogues and interferonalpha have their limitations without exception. There is no effective drug and therapeutic method that can really and truly cure hepatitis B so far. The variability of HBV genome results in that a significant number of patients develop drug resistance during the long-term use of anti-HBV drugs. Hence, it is urgently needed to discover novel targets and develop new drugs against hepatitis B.
Objective:
The review aims to provide the theory support for designing of the anti-HBV innovative drugs by offering a summary of the current situation of antiviral potential targets.
Results And Conclusion:
Since HBV is obligate intracellular parasite, and as such it depends on host cellular components and functions to replicate itself. The targeting both virus and host might be a novel therapeutic option for hepatitis B. Accordingly, we analyse the advances in the study of the potential drug targets for anti-HBV infection, focusing on targeting virus genome, on targeting host cellular functions and on targeting virus-host proteins interactions, respectively. Meanwhile, the immune targets against chronic hepatitis B are also emphasized. In short, the review provides a summary of antiviral therapeutic strategies to target virus factors, host factors and immune factors for future designing of the innovative drug against HBV infection.
Related Concept Videos
What are Viruses?
Hepatic Drug Excretion: Influencing Factors
Introduction to Virus
Viruses of Archaea
Factors Affecting Protein-Drug Binding: Drug-Related Factors
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
Viruses with RNA Genomes

